Impact of Left Ventricular Function and Heart Failure Symptoms on Outcomes Post Ablation of Atrial Fibrillation in Heart Failure

Supplemental Digital Content is available in the text. Background: Recent data demonstrate promising effects on left ventricular dysfunction and left ventricular ejection fraction (LVEF) improvement following ablation for atrial fibrillation (AF) in patients with heart failure. We sought to study the relationship between LVEF, New York Heart Association class on presentation, and the end points of mortality and heart failure admissions in the CASTLE-AF study (Catheter Ablation for Atrial Fibrillation With Heart Failure) population. Furthermore, predictors for LVEF improvement were examined. Methods: The CASTLE-AF patients with coexisting heart failure and AF (n=363) were randomized in a multicenter prospective controlled fashion to ablation (n=179) versus pharmacological therapy (n=184). Left ventricular function and New York Heart Association class were assessed at baseline (after randomization) and at each follow-up visit. Results: In the ablation arm, a significantly higher number of patients experienced an improvement in their LVEF to >35% at the end of the study (odds ratio, 2.17; P<0.001). Compared with the pharmacological therapy arm, both ablation patient groups with severe (<20%) or moderate/severe (≥20% and <35%) baseline LVEF had a significantly lower number of composite end points (hazard ratio [HR], 0.60; P=0.006), all-cause mortality (HR, 0.54; P=0.019), and cardiovascular hospitalizations (HR, 0.66; P=0.017). In the ablation group, New York Heart Association I/II patients at the time of treatment had the strongest improvement in clinical outcomes (primary end point: HR, 0.43; P<0.001; mortality: HR, 0.30; P=0.001). Conclusions: Compared with pharmacological treatment, AF ablation was associated with a significant improvement in LVEF, independent from the severity of left ventricular dysfunction. AF ablation should be performed at early stages of the patient’s heart failure symptoms.

[1]  N. Marrouche,et al.  Atrial fibrillation and cardiac fibrosis. , 2019, European heart journal.

[2]  G. Hindricks,et al.  Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial , 2019, JAMA.

[3]  G. Hasenfuss,et al.  Reverse left ventricular structural remodeling after catheter ablation of atrial fibrillation in patients with preserved left ventricular function: Insights from cardiovascular magnetic resonance native T1 mapping. , 2019, Heart rhythm.

[4]  M. Mayr,et al.  Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology , 2019, European journal of heart failure.

[5]  T. Huynh,et al.  Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials , 2019, BMC Cardiovascular Disorders.

[6]  L. Jordaens,et al.  Catheter Ablation for Atrial Fibrillation with Heart Failure , 2018, The New England journal of medicine.

[7]  S. Prabhu,et al.  Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. , 2017, Journal of the American College of Cardiology.

[8]  Mikhail Chmelevsky,et al.  First-in-Man Analysis of the Relationship Between Electrical Rotors From Noninvasive Panoramic Mapping and Atrial Fibrosis From Magnetic Resonance Imaging in Patients With Persistent Atrial Fibrillation , 2017, Circulation. Arrhythmia and electrophysiology.

[9]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[10]  L. Allen,et al.  Changes in Left Ventricular Ejection Fraction Predict Survival and Hospitalization in Heart Failure With Reduced Ejection Fraction , 2016, Circulation. Heart failure.

[11]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[13]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[14]  Dhanunjaya R. Lakkireddy,et al.  Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial , 2016, Circulation.

[15]  R. D. de Boer,et al.  The fibrosis-cell death axis in heart failure , 2016, Heart Failure Reviews.

[16]  N. Kapur,et al.  Circulating multimarker profile of patients with symptomatic heart failure supports enhanced fibrotic degradation and decreased angiogenesis , 2016, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[17]  Dhanunjaya R. Lakkireddy,et al.  Arrhythmia-Induced Cardiomyopathies , 2015, Contemporary Cardiology.

[18]  S. Heymans,et al.  Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential , 2015, European journal of heart failure.

[19]  David P Kao,et al.  Therapeutic Molecular Phenotype of &bgr;-Blocker–Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy , 2015, Circulation. Cardiovascular genetics.

[20]  V. Melenovský,et al.  Left Atrial Remodeling and Function in Advanced Heart Failure With Preserved or Reduced Ejection Fraction , 2015, Circulation. Heart failure.

[21]  J. Ferreira,et al.  Heart Failure and Atrial Fibrillation: From Basic Science to Clinical Practice , 2015, International journal of molecular sciences.

[22]  Biykem Bozkurt,et al.  2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[23]  A. Boyd,et al.  Left atrial volumes: two-dimensional, three-dimensional, cardiac magnetic resonance and computed tomography measurements , 2014, Current opinion in cardiology.

[24]  M. Metra,et al.  Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives , 2014, International journal of cardiology. Heart & vessels.

[25]  G. Hindricks,et al.  Long-term follow-up after atrial fibrillation ablation in patients with impaired left ventricular systolic function: the importance of rhythm and rate control. , 2014, Heart rhythm.

[26]  Stephane Heymans,et al.  Myocardial Extracellular Matrix: An Ever-Changing and Diverse Entity , 2014, Circulation research.

[27]  Nazem Akoum,et al.  Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. , 2014, JAMA.

[28]  Jamil Mayet,et al.  A Randomized Controlled Trial of Catheter Ablation Versus Medical Treatment of Atrial Fibrillation in Heart Failure (The CAMTAF Trial) , 2014, Circulation. Arrhythmia and electrophysiology.

[29]  A. Kaan,et al.  Ten year survival by NYHA functional class in heart failure outpatients referred to specialized multidisciplinary heart failure clinics 1999 to 2011 , 2013 .

[30]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[31]  Y. Pinto,et al.  Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. , 2011, Cardiovascular research.

[32]  M. Walsh,et al.  Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial , 2009, Circulation.

[33]  R. Wachter,et al.  Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure , 2009, Journal of hypertension.

[34]  Richard Sutton,et al.  Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[35]  K. Stolen,et al.  Heart Rate and New York Heart Association Class Predict Outcomes in Heart Failure Patients , 2007 .

[36]  Ali Ahmed,et al.  A propensity matched study of New York Heart Association class and natural history end points in heart failure. , 2007, The American journal of cardiology.

[37]  B. Gersh,et al.  Atrial Fibrillation and Ventricular Dysfunction: A Vicious Electromechanical Cycle , 2004, Circulation.

[38]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[39]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[40]  H. Klepzig.  [The department of cardiology]. , 1957, Die Medizinische.

[41]  G. Fonarow,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Circulation.

[42]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.